Cargando…

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma

BACKGROUND: EGFR mutation is a common oncogene driver in East Asians with lung adenocarcinoma (LUAD), conferring a favorable prognosis with effective targeted therapy. However, the EGFR mutation is a weak predictor of long-term survival. Therefore, a powerful predictive tool is urgently needed to es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chengming, Zheng, Sufei, Wang, Sihui, Wang, Xinfeng, Feng, Xiaoli, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040386/ https://www.ncbi.nlm.nih.gov/pubmed/33889215 http://dx.doi.org/10.1177/17588359211006949

Ejemplares similares

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
por: Cheng, Chao, et al.
Publicado: (2015)

S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
por: Lu, Zhiliang, et al.
Publicado: (2021)

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
por: Liu, Chengming, et al.
Publicado: (2022)

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations
por: Leal, Letícia Ferro, et al.
Publicado: (2019)

Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
por: Sato, Seijiro, et al.
Publicado: (2018)

PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
por: Mao, Shuangshuang, et al.
Publicado: (2019)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
por: Li, Chenguang, et al.
Publicado: (2011)

Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state
por: Huang, Jianbing, et al.
Publicado: (2020)

Predicting EGFR Mutation in Lung Adenocarcinoma: Development and Validation of the EGFR Mutation Predictive Score (EMPS) in Bali, Indonesia
por: Njoto, Edwin Nugroho, et al.
Publicado: (2023)

Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
por: Gu, Weiquan, et al.
Publicado: (2020)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

External validation of machine learning models including newborn metabolomic markers for postnatal gestational age estimation in East and South-East Asian infants
por: Hawken, Steven, et al.
Publicado: (2021)

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2
por: Wang, Feng, et al.
Publicado: (2021)

Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations
por: Geng, Yimeng, et al.
Publicado: (2020)

Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities
por: Choong, Wai-Kok, et al.
Publicado: (2021)

External validation of the SWEDEHEART score for predicting in-hospital major bleeding among East Asian patients with acute myocardial infarction
por: Liu, Yabin, et al.
Publicado: (2023)

A novel APA-based prognostic signature may predict the prognosis of lung adenocarcinoma in an East Asian population
por: Zhang, Wendi, et al.
Publicado: (2023)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
por: Nishio, Makoto, et al.
Publicado: (2020)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with EGFR Mutation Before Treatment
por: An, Wenting, et al.
Publicado: (2022)

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
por: Wang, Yuxiang, et al.
Publicado: (2022)

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
por: Partheen, Karolina, et al.
Publicado: (2009)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Detection and Quantification of the Harmful Dinoflagellate Margalefidinium polykrikoides (East Asian Ribotype) in the Coastal Waters of China
por: Hu, Jiarong, et al.
Publicado: (2022)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Relationship between the image characteristics of artificial intelligence and EGFR gene mutation in lung adenocarcinoma
por: Zhou, Guoping, et al.
Publicado: (2023)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

External validation of a prognostic index
por: Bonnett, Laura, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d2be48tl04epv6b67rkstc9sk0